Bio-Rad Laboratories, Inc.
Financials
Valuation Metrics
Bio-Rad Laboratories, Inc.'s Market Cap is $8.96B. At end of 2025 it was $8.17B. Ranked #1012 of 3,112 in US market (top 33%), #686 of 1,667 on NYSE (top 41%), #68 of 206 in Health Care Equipment & Services (top 33%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.96B | US#1,012/3,112 Sec#68/206 |
| Revenue | $2.59B | US#1,326/3,112 Sec#81/206 |
| Net Income | $169M | US#1,352/3,112 Sec#65/206 |
| Total Assets | $9.79B | US#998/3,112 Sec#47/206 |
| Net Assets | $6.85B | US#570/3,112 Sec#33/206 |
| Employees | 7,450 | US#700/3,112 Sec#65/206 |
| Value | ||
| P/E | 53.07x | US#1,871/3,112 Sec#94/206 |
| P/B | 1.31x | US#637/3,112 Sec#36/206 |
| P/S | 3.46x | US#1,926/3,112 Sec#133/206 |
| EV/EBITDA | 20.93x | US#1,898/3,112 Sec#87/206 |
| FCF Yield | 3.99% | US#1,520/3,112 Sec#85/206 |
| Profitability | ||
| ROE | 2.46% | US#2,029/3,112 Sec#101/206 |
| ROA | 1.72% | US#1,684/3,112 Sec#100/206 |
| Op. Margin | 9.25% | US#1,687/3,112 Sec#82/206 |
| Revenue Growth | 1.14% | US#2,127/3,112 Sec#163/206 |
| Earnings Growth | -923.59% | US#2,364/3,112 Sec#126/206 |
| Financial Health | ||
| Debt Ratio | 42.89% | US#490/3,112 Sec#58/206 |
| Total Debt | $1.38B | US#1,315/3,112 Sec#69/206 |
| FCF | $357M | US#1,035/3,112 Sec#61/206 |
| Cash | $507M | US#1,061/3,112 Sec#60/206 |
| Current Ratio | 3.21x | US#740/3,112 Sec#77/206 |
| Net Debt/EBITDA | 1.85x | US#1,330/3,112 Sec#78/206 |
| Performance | ||
| 1Y Return | 17.61% | US#1,439/3,112 Sec#99/206 |
| 1M Return | 12.75% | US#384/3,112 Sec#34/206 |
| From 52W High | -2.45% | US#265/3,112 Sec#15/206 |
| 1Y MDD | -28.86% | US#1,298/3,112 Sec#44/206 |
| Trading | ||
| Volume | 187,121 shares | US#2,700/3,112 Sec#191/206 |
| Trading Value | $62M | US#1,223/3,112 Sec#94/206 |
| Per Share | ||
| EPS | $28.17 | US#40/3,112 Sec#4/206 |
| BPS | $276.30 | US#22/3,112 Sec#1/206 |
Company Info
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.